series-c-plus
Stage
About
Apellis Pharmaceuticals is a biopharmaceutical company developing therapies that inhibit the complement system; its lead program, pegcetacoplan, is being developed for retinal disease (geographic atrophy) and other complement-mediated disorders.
Explore Apellis Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.